respiratory
Pulmonary fibrosis

Thumbs down for sildenafil in IPF combo


Combination therapy with nintedanib and sildenafil offers no advantage over nintedanib alone in patients with IPF. The INSTAGE trial, presented at ERS 2018 in Paris and published concurrently in the NEJM, randomised 274 patients across 13 countries to either the...

Combination therapy with nintedanib and sildenafil offers no advantage over nintedanib alone in patients with IPF. The INSTAGE trial, presented...

Read more